ELOCON (mometasone furoate) Cream, 0.1%, Schering NDA 19-625/S-012 & S-013 7/17/02 7/24/02 7/19/02 ELOCON (mometasone furoate) Lotion, 0.1%, Schering NDA 19-796/S-08 & S-015 7/17/02 7/24/02 7/19/02 ELOCON (mometasone furoate) Ointment, 0.1%, Schering NDA 19-543/S-014 12/15/02 1/23/03 12/16/02 ELOCON (mometasone furoate) Ointment, 0.1%, Schering NDA 19-543/S-011 & S-013 Mometasone Furoate Cream USP, 0.1%, Tentatively Approved Altana ANDA 76-171 7/10/02 Mometasone Furoate Ointment USP, 0.1%, Clay-Park Labs, ANDA 76-067 3/18/02 4/10/03 Mometasone Furoate Ointment USP, 0.1%, Tentatively Approved Clay-Park Labs, ANDA 76-067 2/1/02 Mometasone Furoate Topical Solution USP, 0.1%, Tentatively Approved Altana ANDA 75-919 Nasonex (Mometasone Furoate Monohydrate) Aqueous Nasal Spray, Schering Corp. NDA 20-762/S-014 3/3/03 3/10/03 Nasonex Nasal Spray, 50 mcg., Schering Corp. NDA 20-762/S-001 11/19/98 1/12/99 5/25/01 Nasonex Indication: Prophylaxis and treatment of the nasal symptoms of seasonal allergic rhinitis and the treatment of the nasal symptoms of perennial allergic rhinitis, in adults and children 12 years of age and older. Mometasone Furoate Ointment USP, Atrix Mometasone Furoate Topical Solution, Atrix Laboratories, Tentative Approval Nasonex (Mometasone Furoate Monohydrate) Aqueous Nasal Spray, Schering Corp.